fda warning letters compounded semaglutide september 2025 Sends to More Than 50 GLP-1 Compounders and Manufacturers FDA Issues Warning Letters to

Headache, dizziness, nausea and temporary injection-site reactions are also reported

51 subjects with more than 50 non-inflammatory and up to 50 inflammatory acne lesions were enrolled in this study

Hydrophilicity barriers: Peptides generally hydrophilic due to charged amino acids

Risk factors for nonalcoholic steatohepatitis include age older than 45 years, an aspartate transaminase (AST) level greater than the alanine transaminase (ALT) level, diabetes, insulin resistance, low albumin level (less than 3.6 g per dL [36 g per L]), low platelet count (less than 100 10 3 per L [100 10 9 per L]), metabolic syndrome, obesity, and portal hypertension on imaging